AUVI-Q
Commercial- Indications
- Anaphylaxis
Company intelligence / Profile preview
Kaléo
Richmond, Virginia, United Stateskaleo.com ↗
- Ownership
- Private
- Employees
- ~58
- Development stage
- Commercial
01
Overview
Kaléo has successfully commercialized products including AUVI-Q (epinephrine injector) and previously Evzio (opioid overdose treatment). The company is currently developing medical countermeasures under government contracts.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Auto-injection devices for drug delivery
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 asset03
Partnerships
Sanofi (for manufacturing and commercializing AUVI-Q in North America)U.S. Department of DefenseBiomedical Advanced Research and Development Authority (BARDA)
Beyond the preview
Go deeper on Kaléo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kaléo.